CRISPR in HIV: dangers of CCR5 deletion

References

• 1. Cyranoski D. The CRISPR-baby scandal: what's next for human gene-editing. Nature 566(7745), 440–442 (2019).
  Medline CASGoogle Scholar
• 2. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382(6593), 722–725 (1996).
  Medline CASGoogle Scholar
• 3. Stephens JC, Reich DE, Goldstein DB et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62(6), 1507–1515 (1998).
  Medline CASGoogle Scholar
• 4. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring Harb. Perspect Med. 2(8), a006866 (2012).
  MedlineGoogle Scholar
• 5. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 283(20), 2701–2711 (2000).
  Medline CASGoogle Scholar
• 6. Sollitto S, Hoffman S, Mehlman M, Lederman RJ, Youngner SJ, Lederman MM. Intrinsic conflicts of interest in clinical research: a need for disclosure. Kennedy Inst. Ethics J. 13(2), 83–91 (2003).
  MedlineGoogle Scholar
• 7. Rusconi S. Investigators involvement in the care of HIV-infected individuals: the experience in recent clinical trials. J. Acquir. Immune Defic. Syndr. 58(4), e118–e119 (2011).
  MedlineGoogle Scholar
• 8. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. Don't edit the human germ line. Nature 519(7544), 410–411 (2015).
  Medline CASGoogle Scholar
• 9. UNAIDS. 90-90-90: treatment for all. http://www.unaids.org/en/resources/909090
  Google Scholar
• 10. Cohen MS, Chen YQ, McCauley M et al. HPTN 052 study team. antiretroviral therapy for the prevention of HIV-1 transmission. N. Engl. J. Med. 375(9), 830–839 (2016).
  Medline CASGoogle Scholar
• 11. Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA 321(5), 451–452 (2019).
  MedlineGoogle Scholar
• 12. Molina JM, Capitant C, Spire B. ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373(23), 2237–2246 (2015).
  Medline CASGoogle Scholar
• 13. Gao C. The future of CRISPR technologies in agriculture. Nat. Rev. Mol. Cell Biol. 19(5), 275–276 (2018).
  Medline CASGoogle Scholar
• 14. Kyrou K, Hammond A, Galizi R et al. A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes. Nat. Biotechnol. 36(11), 1062–1066 (2018).
  Medline CASGoogle Scholar
• 15. Ledford H. Quest to use CRISPR against disease gains ground. Nature 577(7789), 156 (2020).
  Medline CASGoogle Scholar
• 16. Elvin SJ, Williamson ED, Scott JC et al. Evolutionary genetics: ambiguous role of CCR5 in Y. pestis infection. Nature 430(6998), 417 (2004).
  Medline CASGoogle Scholar
• 17. Glass WG, McDermott DH, Lim JK et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203(1), 35–40 (2006).
  Medline CASGoogle Scholar
• 18. Falcon A, Cuevas MT, Rodriguez-Frandsen A et al. CCR5 deficiency predisposes to fatal outcome in influenza virus infection. J. Gen. Virol. 96(8), 2074–2078 (2015).
  Medline CASGoogle Scholar
• 19. Maestri A, dos Santos MC, Ribeiro-Rodrigues EM et al. The CCR5Δ32 (rs333) polymorphism is not a predisposing factor for severe pandemic influenza in the Brazilian admixed population. BMC Res. Notes 8, 326 (2015).
  MedlineGoogle Scholar
• 20. Matos AR, Martins JSCC, Oliveira MLA, Garcia CC, Siqueira MM. Human CCR5Δ32 (rs333) polymorphism has no influence on severity and mortality of influenza A(H1N1)pdm09 infection in Brazilian patients from the post pandemic period. Infect. Genet. Evol. 67, 55–59 (2019).
  Medline CASGoogle Scholar
• 21. Hütter G, Nowak D, Mossner M et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360(7), 692–698 (2009).
  Medline CASGoogle Scholar
• 22. Rodréguez-Rodríguez DR, Ramírez-Solís R, Garza-Elizondo MA, Garza-Rodríguez ML, Barrera-Saldaña HA. Genome editing: a perspective on the application of CRISPR/Cas9 to study human diseases. Int. J. Mol. Med. 43(4), 1559–1574 (2019).
  MedlineGoogle Scholar